Immunotherapy spinout Annexon Biosciences collected funding from Novartis Venture Fund in a series C round that brought its total funding to $154m.
US-based immunotherapy developer Annexon Biosciences closed a $75m series C round yesterday backed by Novartis Venture Fund, the corporate venturing vehicle owned by pharmaceutical firm Novartis.
Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital, led the round, which included Surveyor Capital, Adage Capital Partners, New Enterprise Associates (NEA), Satter Investment Management and Blackstone Life Sciences, a subsidiary of investment firm Blackstone.
Founded in 2011 as a Stanford University spinout, Annexon is an immunotherapy developer targeting autoimmune,…